Icariin attenuates bleomycin-induced pulmonary fibrosis by targeting Hippo/YAP pathway
Authors:
Open Access
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 143, 112152
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Science and Technology Development Foundation (18401971300)
- National Natural Science Foundation of China (81600309)
- Fudan University
- Natural Science Foundation of Shanghai Municipality (16ZR1404800)
This publication has 28 references indexed in Scilit:
- Regulation of Th17/Treg function contributes to the attenuation of chronic airway inflammation by icariin in ovalbumin-induced murine asthma modelImmunobiology, 2015
- Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba EpimediiLife Sciences, 2015
- Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2015
- Pharmacologic therapies for idiopathic pulmonary fibrosis, past and futureAnnals of Medicine, 2015
- The Merits of Unconscious Thought in Rule DetectionPLOS ONE, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Icariin attenuates high glucose‐induced type IV collagen and fibronectin accumulation in glomerular mesangial cells by inhibiting transforming growth factor‐β production and signalling through G protein‐coupled oestrogen receptor 1Clinical and Experimental Pharmacology and Physiology, 2013
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Murine models of pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in ratsThorax, 2003